Dr. Bekaii-Saab on the Impact of COVID-19 on Telemedicine

Video

In Partnership With:

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the impact of the novel coronavirus 2019 (COVID-19) on telemedicine.

COVID-19 has created a pandemic of such magnitude that the majority of the population has never experienced before, explains Bekaii-Saab.

Moreover, COVID-19 raises specific concerns regarding older individuals with comorbidities as they are at an increased risk of dying from the virus, says Bekaii-Saab.

To minimize the number of patients exposed to COVID-19, Mayo Clinic implemented safety measures like telemedicine early on, explains Bekaii-Saab. Though telemedicine was used prior to the outbreak, its role has grown significantly over the course of the pandemic. It is likely that telehealth will retain its role after COVID-19 has subsided, concludes Bekaii-Saab.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD